Evaluaciones económicas en salud: ¿qué debemos tener en cuenta al leerlas?
DOI:
https://doi.org/10.52787/agl.v53i2.332Palabras clave:
Evaluaciones económicas en salud, sistema de saludResumen
Las evaluaciones económicas en salud representan un
abordaje técnico que aporta información en el proceso de
toma de decisiones para incorporar o no un medicamento,
un dispositivo o un método diagnóstico en un sistema
de salud. Pero, antes de describirlas, repasaremos el marco
conceptual que las contiene.
Citas
-1. World Bank. The World Bank Group’s Response to the COVID-19 (coronavirus) Pandemic. Disponible en: https://www.worldbank.org/en/who-we-are/news/coronavirus-covid19
-2. MacDonald R, Horton R. Trade and health: time for the health sector to get involved. Lancet. 2009 Jan 24;373(9660):273-4.
-3. Human Rights. World Health Organization. 2022. Disponible en: https://www.who.int/news-room/fact-sheets/detail/human-rights-and-health
-4. Transforming our world: the 2030 Agenda for Sustainable Development. Resolution adopted by the General Assembly on 25 September 2015. United Nations. Disponible en: https://documents-dds-ny.un.org/doc/UNDOC/GEN/N15/291/89/PDF/N1529189.pdf?OpenElement
-5. Meltzer MI. Introduction to health economics for physicians. Lancet. 2001 Sep 22;358(9286):993-8. DOI: 10.1016/S0140-6736(01)06107-4. PMID: 11583768.
-6. Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet. 2017 Jul 22;390(10092):415-423.
-7. The GRADE Working Group. Disponible en: https://www.gradeworkinggroup.org/
-8. Levels of Evidence. Disponible en: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence
-9. Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res. 2021 Jul-Sep;12(3):171-174. DOI: 10.4103/picr.picr_62_21. Epub 2021 Jul 7. PMID: 34386383; PMCID: PMC8323556.
-10. Patient-Reported Outcomes and other Clinical Outcome Assessments. Food and Drug Administation. Disponible en: https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-patient-reported-outcomes-and-other-clinical-outcomeassessments#:~:text=Patient%2Dreported%20outcomes%20(PROs)%3A,such%20as%20a%20pain%20scale
-11. QALY. Glossary. NICE. Disponible en: https://www.nice.org.uk/glossary?letter=q
-12. Ma C, Congly SE, Chyou DE, Ross-Driscoll K, Forbes N, Tsang ES, Sussman DA, Goldberg DS. Factors Associated With Geographic Disparities in Gastrointestinal Cancer Mortality in the United States. Gastroenterology. 2022 Aug;163(2):437-448.e1. DOI: 10.1053/j.gastro.2022.04.019. Epub 2022 Apr 25. PMID: 35483444; PMCID: PMC9703359.
-13. Boissonnet CP, Giorgi MA, Carosella L, Brescacin C, Pissinis J, Guetta JN. Clinical outcomes after transcatheter aortic valve replacement in South America: A centre-level systematic review and meta-analysis of observational data. J Eval Clin Pract. 2021 Aug;27(4):785-798. DOI: 10.1111/jep.13469. Epub 2020 Sep 2. PMID: 32881274.
-14. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009 Jun;12(4):409-18. DOI: 10.1111/j.1524-4733.2008.00489.x. Epub 2009 Jan 12. PMID: 19900249.
-15. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2008. London: NICE; 2008. Disponible en: https://www.nice.org.uk/process/pmg9/resources/guideto-the-methods-of-technology-appraisal-2013-pdf-2007975843781
-16. Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023 Jun;11(6):e833-e842. DOI: 10.1016/S2214-109X(23)00162-6. PMID: 37202020.
-17. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022 Jun;25(6):1060. DOI: 10.1016/j.jval.2022.03.002. Epub 2022 Apr 23. Erratum for: Value Health. 2022 Jan;25(1):10-31. PMID: 35474251.
-18. Giorgi MA, Boissonnet CP, Luque PS, Piastrella J, Porley C, Ditata F, Volman S. Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina. Health Econ Rev. 2023 Feb 18;13(1):13. DOI: 10.1186/s13561-023-00427-w. PMID: 36808581; PMCID: PMC9938575.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Mariano Giorgi
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.